NCT01461577View on ClinicalTrials.gov

Effectiveness and Safety of Treatment of Insulin Glargine in Type 2 Diabetes Mellitus Following Glucagon-like Peptide-1 (GLP-1) Failure

PHASE4CompletedINTERVENTIONAL
Enrollment

89

Participants

Timeline

Start Date

November 30, 2011

Primary Completion Date

December 31, 2012

Study Completion Date

December 31, 2012

Conditions
Type 2 Diabetes Mellitus
Interventions
DRUG

INSULIN GLARGINE HOE 901

Pharmaceutical form:solution Route of administration: subcutaneous

Trial Locations (1)

Unknown

Administrative office, Tokyo

Sponsors

Lead Sponsor

Sanofi
All Listed Sponsors
lead

Sanofi

INDUSTRY